Long-Term Outcomes of Birdshot Chorioretinopathy Treated with Corticosteroids: A Case Reports

Purpose: To report the progression of patients diagnosed with birdshot chorioretinopathy (BSCR) initially treated with corticosteroids. Methods: We included 39 BSCR patients that were followed for =1 year. We analyzed their progression under treatment after 1, 3, 6 months, 1 year, and at the end of follow-up. In order to determine the efficiency of initial loading doses, patients were classified into two groups according to their initial treatment: methylprednisolone followed by prednisone (n = 28) and prednisone alone (n = 11). Results: At the end of follow-up, 31/39 (79.5%) patients had reached inflammation control. Thirteen out of 28 (46.4%) and 6/11 (54.5%) patients were treated exclusively with corticosteroids, and 18/19 (94.7%) of them had reached inflammation control at the end of follow-up; their mean (range) corticosteroid dose was 3.5 (0-10) mg/day. Conclusions: We found that the prolonged corticosteroid therapy treatment strategy resulted in inflammation control in half of BSCR patients. This control was maintained with low doses of cortisone, usually <5 mg/day.

Automated summary

The purpose of this study was to report the progression of patients initially treated with corticosteroids for birdshot chorioretinopathy (BSCR). A total of 39 BSCR patients were included in the study and followed up for =1 year. The study found that prolonged corticosteroid therapy resulted in inflammation control in 50% of BSCR patients, with low doses of cortisone (<5 mg/day) being sufficient to maintain this control.